Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

Speciality: Oncology


Speaker:

Dr. Pawan Kumar Singh | Associate director BLK Max Hospital

Dr. Roshan Dixit | Consultant Aakash Hospital

Dr. Manisha Jain | Consultant Medanta Hospital

Dr. Avruti Baweja | Asst.Prof., Himalayan Institute of Medical Sciences

Description:

Welcome to this insightful expert discussion on the treatment paradigm for patients with relapsed/refractory (R/R) adult B-cell acute lymphoblastic leukemia (ALL). Renowned hematologists and oncologists, Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja, share their valuable perspectives on the latest advancements, challenges, and emerging therapies in managing this aggressive condition. The panel delves into key topics such as novel immunotherapies, targeted treatments, and personalized approaches that are reshaping outcomes for R/R B-cell ALL patients.

The experts critically evaluate current treatment strategies, including CAR T-cell therapy, bispecific antibodies, and small-molecule inhibitors, while discussing real-world clinical experiences and patient selection criteria. They also highlight the importance of multidisciplinary care and the need for early intervention to improve survival rates. Their in-depth analysis provides clinicians with practical insights to navigate complex treatment decisions in this rapidly evolving field.

Don’t miss this engaging and informative session that bridges cutting-edge research with clinical practice. Stay tuned for more expert-led discussions that aim to enhance knowledge and improve patient care in hematologic malignancies. Watch the full video to gain comprehensive insights from these distinguished thought leaders!

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot